查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1566359

血浆蛋白分解酵素C1抑制剂市场，规模，占有率，趋势，产业分析报告:各类药物，各剂型，各流通管道，各地区 - 市场预测，2024年～2032年

Plasma Protease C1-inhibitor Market Size, Share, Trends, and Industry Analysis Report: By Drug Class, Dosage Form, Distribution Channel, and Region - Market Forecast, 2024 - 2032
出版日期: | 出版商: Polaris Market Research | 英文 117 Pages | 商品交期: 最快1-2个工作天内

价格

根据 Polaris Market Research 的最新研究，血浆蛋白酶 C1 抑制剂的全球市场预计到 2032 年将达到 79.6 亿美元。该报告提供了对当前市场动态的详细见解，并对未来市场成长进行了分析。

血浆蛋白酶 C1 抑制剂 (C1-INH) 市场近年来由于配方、安全性、治疗功效和适应症的扩大而经历了重大的技术创新。从静脉注射转向皮下注射代表了重大飞跃，提供了更大的便利性并可能提高患者的依从性。同时，纯化製程的改进提高了 C1-INH 製剂的安全性，最大限度地减少副作用并最大限度地提高治疗效果。

对传统 C1-INH 替代疗法以外的新作用机制的持续研究可能会扩大治疗选择，并解决更广泛的遗传性血管水肿 (HAE) 和相关疾病患者的问题。例如，根据阿姆斯特丹 UMC 内科医生和研究人员报道，2024 年 6 月，两种新药 donidalorsen 和 sevetralstat 在治疗遗传性血管水肿方面显示出有希望的结果。

血浆蛋白酶 C1 抑制剂 (C1-INH) 市场的特征是全球 HAE 诊断增加推动需求不断增长。这种罕见的遗传疾病需要有效的 C1-INH 替代疗法，促使治疗方案不断进步。给药方法和配方的创新旨在提高患者的便利性和依从性，而地理扩张的目标是改善全球这些特殊疗法的可及性。竞争格局依然活跃，製药公司投资于研发，并得到促进市场成长和新疗法采用的监管措施的支持。以患者为中心的计划和宣传工作进一步有助于改善 HAE 患者的治疗结果和生活质量，塑造 C1-INH 市场的未来轨迹。

血浆蛋白酶 C1 抑制剂市场报告重点

C1 抑制剂预计将在 2023 年引领市场，由于关键参与者的持续研发努力，选择性缓激肽 B2 受体拮抗剂预计将显示出最快的成长。

冷冻干燥製剂因其稳定性、延长的保质期以及方便的储存和运输而成为 C1 抑制剂治疗的首选，并且由于其能够确保患者和医疗保健提供者的疗效和便利性而获得市场动力。

医院药局因其广泛的可及性、法规遵循以及对血浆蛋白酶 C1 抑制剂等特殊疗法的有效管理而引领血浆蛋白酶 C1 抑制剂市场。

由于高额医疗支出、先进的基础设施、广泛的研究以及血浆蛋白酶 C1 抑制剂治疗遗传性血管性水肿等罕见疾病的大量使用，北美将在 2023 年引领市场。

全球领先的血浆蛋白酶 C1 抑制剂公司包括 BioCryst Pharmaceuticals, Inc.、CENTOGENE NV、CSL、Fresenius Kabi、Ionis Pharmaceuticals, Inc.、KalVista Pharmaceuticals、Pharming、Sanquin、Shire plc 和 Takeda Pharmaceuticals。

目录

第1章 简介

第2章 摘要整理

第3章 调查手法

第4章 全球血浆蛋白分解酵素C1抑制剂市场洞察

  • 应用概述
  • 血浆蛋白分解酵素C1抑制剂市场动态
    • 促进因素和机会
      • 临床试验和研究活动的增加推动市场成长
      • 医疗保健领域支出的增加推动血浆蛋白酶 C1 抑制剂市场成长
    • 阻碍因素与课题
      • 治疗费的急剧上升
  • PESTEL分析
  • 血浆蛋白分解酵素C1抑制剂市场应用趋势
  • 价值链分析
  • COVID-19影响分析

第5章 全球血浆蛋白分解酵素C1抑制剂市场:各类药物

  • 主要调查结果
  • 简介
  • C1抑制剂
  • 激肽释放酶抑制剂
  • 选择性缓激肽 B2 受体拮抗剂

第6章 全球血浆蛋白分解酵素C1抑制剂市场:各剂型

  • 主要调查结果
  • 简介
  • 冷冻干燥
  • 注射剂

第7章 全球血浆蛋白分解酵素C1抑制剂市场:各流通管道

  • 主要调查结果
  • 简介
  • 医院药局
  • 零售药局
  • 线上药局

第8章 全球血浆蛋白分解酵素C1抑制剂市场:各地区

  • 主要调查结果
  • 简介
    • 血浆蛋白分解酵素C1抑制剂市场评估:地区，2019年～2032年
  • 北美
    • 北美:各类药物，2019年～2032年
    • 北美:各剂型，2019年～2032年
    • 北美:各流通管道，2019年～2032年
    • 美国
    • 加拿大
  • 欧洲
    • 欧洲:各类药物，2019年～2032年
    • 欧洲:各剂型，2019年～2032年
    • 欧洲:各流通管道，2019年～2032年
    • 英国
    • 法国
    • 德国
    • 义大利
    • 西班牙
    • 荷兰
    • 俄罗斯
    • 其他欧洲
  • 亚太地区
    • 亚太地区:各类药物，2019年～2032年
    • 亚太地区:各剂型，2019年～2032年
    • 亚太地区:各流通管道，2019年～2032年
    • 中国
    • 印度
    • 马来西亚
    • 日本
    • 印尼
    • 韩国
    • 澳洲
    • 其他亚太地区
  • 中东·非洲
    • 中东·非洲:各类药物，2019年～2032年
    • 中东·非洲:各剂型，2019年～2032年
    • 中东·非洲:各流通管道，2019年～2032年
    • 沙乌地阿拉伯
    • 阿拉伯联合大公国
    • 以色列
    • 南非
    • 其他中东和非洲
  • 南美
    • 南美:各类药物，2019年～2032年
    • 南美:各剂型，2019年～2032年
    • 南美:各流通管道，2019年～2032年
    • 墨西哥
    • 巴西
    • 阿根廷
    • 其他南美国家

第9章 竞争情形

  • 扩大和收购的分析
    • 扩大
    • 收购
  • 联盟/合作/协定/公开

第10章 企业简介

  • BioCryst Pharmaceuticals, Inc.
  • CENTOGENE N.V.
  • CSL
  • Fresenius Kabi
  • Ionis Pharmaceuticals, Inc.
  • KalVista Pharmaceuticals
  • Pharming
  • Sanquin
  • Shire plc
  • Takeda Pharmaceutical Company Limited
Product Code: PM5058

The global plasma protease C1-inhibitor market size is expected to reach USD 7.96 billion by 2032, according to a new study by Polaris Market Research. The report "Global Plasma Protease C1-inhibitor Market Size, Share, Trends, Industry Analysis Report: By Drug Class (C1-inhibitors, Kallikrein Inhibitor, and Selective Bradykinin B2 Receptor), Dosage Form, Distribution Channel, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2024 - 2032." gives a detailed insight into current market dynamics and provides analysis on future market growth.

The market for plasma protease C1-inhibitor (C1-INH) has witnessed substantial innovation in recent years, driven by advancements in formulation, safety, therapeutic efficacy, and expanded indications. The shift from intravenous to subcutaneous administration represents a significant leap forward, offering improved convenience and potentially enhancing patient compliance. Concurrently, improvements in purification processes have bolstered the safety profiles of C1-INH products, minimized adverse reactions and maximizing therapeutic effectiveness.

Ongoing research into novel mechanisms of action beyond traditional C1-INH replacement therapy holds promise for broadening treatment options, potentially catering to a wider range of patients with hereditary angioedema (HAE) and related conditions. For instance, in June 2024, two new medicines, donidalorsen and sebetralstat, showed promising results in treating hereditary angioedema, as reported by an internist and researcher from Amsterdam UMC.

The market for plasma protease C1-inhibitor (C1-INH) is characterized by a rising demand driven by increasing diagnoses of HAE globally. This rare genetic disorder necessitates effective C1-INH replacement therapies, prompting ongoing advancements in treatment options. Innovations in delivery methods and formulations aim to enhance patient convenience and adherence, while geographic expansion efforts seek to improve access to these specialized therapies worldwide. The competitive landscape remains active with pharmaceutical companies investing in research and development, supported by regulatory initiatives that facilitate market growth and adoption of new therapies. Patient-centric programs and advocacy efforts further contribute to improving outcomes and quality of life for individuals living with HAE, shaping the future trajectory of the C1-INH market.

Plasma Protease C1-inhibitor Market Report Highlights

C1-inhibitors led the market in 2023, with selective bradykinin B2 receptor antagonists expected to show the fastest growth due to ongoing R&D efforts by key industry players.

Lyophilized segments dominated the market with their stability, extended shelf life, and convenient storage and transport, making them favored for C1-inhibitor therapy, ensuring effectiveness and ease for patients and providers.

Hospital pharmacies led the plasma protease C1-inhibitor market due to their wide accessibility, regulatory adherence, and effective management of specialized therapies such as plasma protease C1-inhibitor.

North America led the market in 2023, owing to its substantial healthcare spending, advanced infrastructure, extensive research, and significant use of plasma protease C1-inhibitor therapies for rare diseases such as hereditary angioedema.

The global key plasma protease C1-inhibitor market players include BioCryst Pharmaceuticals, Inc.; CENTOGENE N.V.; CSL; Fresenius Kabi; Ionis Pharmaceuticals, Inc.; KalVista Pharmaceuticals; Pharming; Sanquin; Shire plc; and Takeda Pharmaceutical Company Limited.

Polaris Market Research has segmented the Plasma Protease C1-inhibitor market report based on drug class, dosage form, distribution channel, and region:

By Drug Class Outlook (Revenue - USD billion, 2019 - 2032)

  • C1-inhibitors
  • C1-esterase Inhibitor
  • Recombinant Inhibitor
  • Kallikrein Inhibitor
  • Selective Bradykinin B2 Receptor Antagonist

By Dosage Form Outlook (Revenue - USD billion, 2019 - 2032)

  • Lyphophlised
  • Injectables

By Distribution Channel Outlook (Revenue - USD billion, 2019 - 2032)

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Regional Outlook (Revenue - USD billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Australia
  • Vietnam
  • Rest of Asia Pacific
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Plasma Protease C1-inhibitor Market Insights

  • 4.1. Plasma Protease C1-inhibitor Market - Application Snapshot
  • 4.2. Plasma Protease C1-inhibitor Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increasing Clinical Trials and Research Initiatives is Driving the Market Growth
      • 4.2.1.2. Rising Expenditure in Healthcare Sector Driving Plasma Protease C1-Inhibitor Market Growth
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High Cost of Treatment
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Plasma Protease C1-inhibitor Market Application Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Plasma Protease C1-inhibitor Market, by Drug Class

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • 5.3. C1-Inhibitor
    • 5.3.1. Global Plasma Protease C1-inhibitor Market, by C1-Inhibitor, by Region, 2019-2032 (USD billion)
      • 5.3.1.1 C1-esterase Inhibitor
      • 5.3.1.1.1 Global Plasma Protease C1-inhibitor Market, by C1-esterase Inhibitor, by Region, 2019-2032 (USD billion)
      • 5.3.1.2 Recombinant Inhibitor
      • 5.3.1.1.2 Global Plasma Protease C1-inhibitor Market, by Recombinant Inhibitor, by Region, 2019-2032 (USD billion)
  • 5.4. Kallikrein Inhibitor
    • 5.4.1. Global Plasma Protease C1-inhibitor Market, by Kallikrein Inhibitor, by Region, 2019-2032 (USD billion)
  • 5.5. Selective Bradykinin B2 Receptor Antagonist
    • 5.5.1. Global Plasma Protease C1-inhibitor Market, by Selective Bradykinin B2 Receptor Antagonist, by Region, 2019-2032 (USD billion)

6. Global Plasma Protease C1-inhibitor Market, by Dosage Form

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • 6.3. Lyphophlised
    • 6.3.1. Global Plasma Protease C1-inhibitor Market, by Lyphophlised, by Region, 2019-2032 (USD billion)
  • 6.4. Injectables
    • 6.4.1. Global Plasma Protease C1-inhibitor Market, by Injectables, by Region, 2019-2032 (USD billion)

7. Global Plasma Protease C1-inhibitor Market, by Distribution Channel

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • 7.3. Hospital Pharmacies
    • 7.3.1. Global Plasma Protease C1-inhibitor Market, by Hospital Pharmacies, By Region, 2019-2032 (USD billion)
  • 7.4. Retail Pharmacies
    • 7.4.1. Global Plasma Protease C1-inhibitor Market, by Retail Pharmacies, By Region, 2019-2032 (USD billion)
  • 7.5. Online Pharmacies
    • 7.5.1. Global Plasma Protease C1-inhibitor Market, by Online Pharmacies, By Region, 2019-2032 (USD billion)

8. Global Plasma Protease C1-inhibitor Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Plasma Protease C1-inhibitor Market Assessment, By Geography, 2019-2032 (USD billion)
  • 8.3. Plasma Protease C1-inhibitor Market - North America
    • 8.3.1. North America: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
    • 8.3.2. North America: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
    • 8.3.3. North America: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
    • 8.3.4. Plasma Protease C1-inhibitor Market - U.S.
      • 8.3.4.1. U.S.: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
      • 8.3.4.2. U.S.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
      • 8.3.4.3. U.S.: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
    • 8.3.5. Plasma Protease C1-inhibitor Market - Canada
      • 8.3.5.1. Canada: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
      • 8.3.5.2. Canada.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
      • 8.3.5.3. Canada: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • 8.4. Plasma Protease C1-inhibitor Market - Europe
    • 8.4.1. Europe: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
    • 8.4.2. Europe.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
    • 8.4.3. Europe: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
    • 8.4.4. Plasma Protease C1-inhibitor Market - UK
      • 8.4.4.1. UK: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
      • 8.4.4.2. UK.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
      • 8.4.4.3. UK: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
    • 8.4.5. Plasma Protease C1-inhibitor Market - France
      • 8.4.5.1. France: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
      • 8.4.5.2. France.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
      • 8.4.5.3. France: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
    • 8.4.6. Plasma Protease C1-inhibitor Market - Germany
      • 8.4.6.1. Germany: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
      • 8.4.6.2. Germany.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
      • 8.4.6.3. Germany: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
    • 8.4.7. Plasma Protease C1-inhibitor Market - Italy
      • 8.4.7.1. Italy: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
      • 8.4.7.2. Italy.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
      • 8.4.7.3. Italy: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
    • 8.4.8. Plasma Protease C1-inhibitor Market - Spain
      • 8.4.8.1. Spain: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
      • 8.4.8.2. Spain.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
      • 8.4.8.3. Spain: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
    • 8.4.9. Plasma Protease C1-inhibitor Market - Netherlands
      • 8.4.9.1. Netherlands: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
      • 8.4.9.2. Netherlands.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
      • 8.4.9.3. Netherlands: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
    • 8.4.10. Plasma Protease C1-inhibitor Market - Russia
      • 8.4.10.1. Russia: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
      • 8.4.10.2. Russia.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
      • 8.4.10.3. Russia: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
    • 8.4.11. Plasma Protease C1-inhibitor Market - Rest of Europe
      • 8.4.11.1. Rest of Europe: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
      • 8.4.11.2. Rest of Europe.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
      • 8.4.11.3. Rest of Europe: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • 8.5. Plasma Protease C1-inhibitor Market - Asia Pacific
    • 8.5.1. Asia Pacific: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
    • 8.5.2. Asia Pacific.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
    • 8.5.3. Asia Pacific: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
    • 8.5.4. Plasma Protease C1-inhibitor Market - China
      • 8.5.4.1. China: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
      • 8.5.4.2. China.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
      • 8.5.4.3. China: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
    • 8.5.5. Plasma Protease C1-inhibitor Market - India
      • 8.5.5.1. India: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
      • 8.5.5.2. India.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
      • 8.5.5.3. India: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
    • 8.5.6. Plasma Protease C1-inhibitor Market - Malaysia
      • 8.5.6.1. Malaysia: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
      • 8.5.6.2. Malaysia.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
      • 8.5.6.3. Malaysia: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
    • 8.5.7. Plasma Protease C1-inhibitor Market - Japan
      • 8.5.7.1. Japan: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
      • 8.5.7.2. Japan.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
      • 8.5.7.3. Japan: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
    • 8.5.8. Plasma Protease C1-inhibitor Market - Indonesia
      • 8.5.8.1. Indonesia: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
      • 8.5.8.2. Indonesia.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
      • 8.5.8.3. Indonesia: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
    • 8.5.9. Plasma Protease C1-inhibitor Market - South Korea
      • 8.5.9.1. South Korea: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
      • 8.5.9.2. South Korea: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
      • 8.5.9.3. South Korea: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
    • 8.5.10. Plasma Protease C1-inhibitor Market - Australia
      • 8.5.10.1. Australia: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
      • 8.5.10.2. Australia: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
      • 8.5.10.3. Australia: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
    • 8.5.11. Plasma Protease C1-inhibitor Market - Rest of Asia Pacific
      • 8.5.11.1. Rest of Asia Pacific: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
      • 8.5.11.2. Rest of Asia Pacific: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
      • 8.5.11.3. Rest of Asia Pacific: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • 8.6. Plasma Protease C1-inhibitor Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
    • 8.6.2. Middle East & Africa.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
    • 8.6.3. Middle East & Africa: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
    • 8.6.4. Plasma Protease C1-inhibitor Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
      • 8.6.4.2. Saudi Arabia.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
      • 8.6.4.3. Saudi Arabia: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
    • 8.6.5. Plasma Protease C1-inhibitor Market - UAE
      • 8.6.5.1. UAE: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
      • 8.6.5.2. UAE.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
      • 8.6.5.3. UAE: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
    • 8.6.6. Plasma Protease C1-inhibitor Market - Israel
      • 8.6.6.1. Israel: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
      • 8.6.6.2. Israel.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
      • 8.6.6.3. Israel: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
    • 8.6.7. Plasma Protease C1-inhibitor Market - South Africa
      • 8.6.7.1. South Africa: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
      • 8.6.7.2. South Africa.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
      • 8.6.7.3. South Africa: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
    • 8.6.8. Plasma Protease C1-inhibitor Market - Rest of Middle East & Africa
      • 8.6.8.1. Rest of Middle East & Africa: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
      • 8.6.8.2. Rest of Middle East & Africa: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
      • 8.6.8.3. Rest of Middle East & Africa: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • 8.7. Plasma Protease C1-inhibitor Market - Latin America
    • 8.7.1. Latin America: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
    • 8.7.2. Latin America.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
    • 8.7.3. Latin America: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
    • 8.7.4. Plasma Protease C1-inhibitor Market - Mexico
      • 8.7.4.1. Mexico: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
      • 8.7.4.2. Mexico.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
      • 8.7.4.3. Mexico: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
    • 8.7.5. Plasma Protease C1-inhibitor Market - Brazil
      • 8.7.5.1. Brazil: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
      • 8.7.5.2. Brazil.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
      • 8.7.5.3. Brazil: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
    • 8.7.6. Plasma Protease C1-inhibitor Market - Argentina
      • 8.7.6.1. Argentina: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
      • 8.7.6.2. Argentina.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
      • 8.7.6.3. Argentina: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
    • 8.7.7. Plasma Protease C1-inhibitor Market - Rest of Latin America
      • 8.7.7.1. Rest of Latin America: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
      • 8.7.7.2. Rest of Latin America.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
      • 8.7.7.3. Rest of Latin America: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. BioCryst Pharmaceuticals, Inc.
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. CENTOGENE N.V.
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. CSL
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Fresenius Kabi
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Ionis Pharmaceuticals, Inc.
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. KalVista Pharmaceuticals
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Pharming
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Sanquin
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Shire plc
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Takeda Pharmaceutical Company Limited
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development

List of Tables

  • Table 1 Global Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 2 Global Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 3 Global Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 4 Plasma Protease C1-inhibitor Market Assessment, By Geography, 2019-2032 (USD billion)
  • Table 5 North America: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 6 North America: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 7 North America: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 8 U.S.: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 9 U.S.: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 10 U.S.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 11 Canada: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 12 Canada: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 13 Canada: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 14 Europe: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 15 Europe: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 16 Europe: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 17 UK: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 18 UK: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 19 UK: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 20 France: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 21 France: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 22 France: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 23 Germany: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 24 Germany: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 25 Germany: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 26 Italy: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 27 Italy: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 28 Italy: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 29 Spain: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 30 Spain: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 31 Spain: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 32 Netherlands: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 33 Netherlands: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 34 Netherlands: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 35 Russia: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 36 Russia: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 37 Russia: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 38 Rest of Europe: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 39 Rest of Europe: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 40 Rest of Europe: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 41 Asia Pacific: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 42 Asia Pacific: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 43 Asia Pacific: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 44 China: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 45 China: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 46 China: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 47 India: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 48 India: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 49 India: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 50 Malaysia: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 51 Malaysia: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 52 Malaysia: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 53 Japan: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 54 Japan: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 55 Japan: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 56 Indonesia: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 57 Indonesia: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 58 Indonesia: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 59 South Korea: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 60 South Korea: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 61 South Korea: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 62 Australia: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 63 Australia: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 64 Australia: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 65 Rest of Asia Pacific: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 66 Rest of Asia Pacific: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 67 Rest of Asia Pacific: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 68 Middle East & Africa: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 69 Middle East & Africa: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 70 Middle East & Africa: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 71 Saudi Arabia: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 72 Saudi Arabia: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 73 Saudi Arabia: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 74 UAE: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 75 UAE: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 76 UAE: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 77 Israel: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 78 Israel: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 79 Israel: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 80 South Africa: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 81 South Africa: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 82 South Africa: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 83 Rest of Middle East & Africa: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 84 Rest of Middle East & Africa: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 85 Rest of Middle East & Africa: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 86 Latin America: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 87 Latin America: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 88 Latin America: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 89 Mexico: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 90 Mexico: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 91 Mexico: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 92 Brazil: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 93 Brazil: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 94 Brazil: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 95 Argentina: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 96 Argentina: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 97 Argentina: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
  • Table 98 Rest of Latin America: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
  • Table 99 Rest of Latin America: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
  • Table 100 Rest of Latin America: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)

List of Figures

  • Figure 1. Global Plasma Protease C1-inhibitor Market, 2019-2032 (USD billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Distribution Channel
  • Figure 7. Global Plasma Protease C1-inhibitor Market, by Distribution Channel, 2023 & 2032 (USD billion)
  • Figure 8. Market by Drug Class
  • Figure 9. Global Plasma Protease C1-inhibitor Market, by Drug Class, 2023 & 2032 (USD billion)
  • Figure 10. Market by Dosage Form
  • Figure 11. Global Plasma Protease C1-inhibitor Market, by Dosage Form, 2023 & 2032 (USD billion)
  • Figure 12. Plasma Protease C1-inhibitor Market Assessment, By Geography, 2019-2032 (USD billion)
  • Figure 13. Strategic Analysis - Plasma Protease C1-inhibitor Market